Tom Equels, CEO of AIM ImmunoTech provides a corporate update and reiterates focus on driving Ampligen forward in pancreatic cancer
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
Seeking Alpha / 1 hour ago 1 Views
Tom Equels, CEO of AIM ImmunoTech provides a corporate update and reiterates focus on driving Ampligen forward in pancreatic cancer
Comments